Valor202020212022202320242025TTMGastos comerciales, generales y administrativos743.57 M860.09 M863.75 M929.87 M995.27 M720.17 M720.17 MInvestigación y desarrollo119.75 M130.84 M153.82 M154.35 M161.67 M144.78 M144.78 MBeneficio operativo423.07 M628.1 M499.73 M506.31 M151.01 M118.37 M-114.14 MTotal de ingresos no operativos20.34 M20.62 M21.79 M-13.65 M-107.31 M28.62 M28.62 MGastos por intereses, netos de intereses capitalizados66.49 M56.97 M54.26 M85.08 M83.54 M100.22 M100.22 MIngresos no operativos, una vez deducidos los gastos por intereses-46.16 M-36.34 M-32.47 M-98.73 M-190.86 M-71.6 M-71.6 MIngresos/gastos extraordinarios———————Beneficio antes de impuestos357.73 M559.47 M445.92 M434.01 M75.48 M24.55 M24.55 MParticipación en los beneficios———————Impuestos21.93 M74.35 M83 M76.44 M5.32 M-33.98 M-33.98 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas335.8 M485.12 M362.92 M357.57 M70.16 M58.53 M-194.74 MOperaciones suspendidas-477 K255 K223 K-1.24 M-487 K-964.17 M-710.9 MBeneficio neto335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-905.64 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-905.64 MBeneficio básico por acción7.2110.387.747.581.49-20.3-20.54Beneficio por acción diluido7.0910.237.687.531.48-20.25-20.55Número medio de acciones ordinarias46.49 M46.77 M46.9 M46.98 M46.84 M44.62 M178.91 MAcciones diluidas47.29 M47.43 M47.31 M47.3 M47.09 M44.72 M179.22 MEBITDA427.5 M632.59 M503.78 M525.32 M394.43 M127.87 M1.39 BEBIT195.82 M390.73 M269.13 M279.8 M116.41 M-54.54 M912.02 MCosto de los ingresos1.21 B1.26 B1.26 B1.33 B1.34 B871.96 M871.96 MOtros costes de producción———————Amortización y depreciación (flujo de caja)231.68 M241.85 M234.64 M245.52 M278.02 M182.41 M478.02 M
Teleflex Incorporated
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer is Liam J. Kelly; Kelly is also the company's president and former chief operating officer.